The USFDA’s tentative approval means Biocon Pharma’s Rifaximin 550 mg meets regulatory requirements but cannot be marketed in the US yet due to patents or exclusivity on the original drugThe USFDA’s tentative approval means Biocon Pharma’s Rifaximin 550 mg meets regulatory requirements but cannot be marketed in the US yet due to patents or exclusivity on the original drug Latest News [ SOBAN NEWS: International and National ]
